Search results for " Liver injury"

showing 10 items of 77 documents

Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo

2010

Background & Aims Apoptosis is crucially involved in acute and chronic liver injury, including viral, cholestatic, toxic, and metabolic liver disease. Additionally, dysregulation of apoptosis signaling pathways has been implicated in hepatocarcinogenesis. The most prominent members of the apoptosis-mediating tumor necrosis factor receptor superfamily are the TNF-R1 (CD120a) and the CD95 (Apo-1/Fas) receptor. Although extensively studied, the intracellular signaling events in hepatocytes are only incompletely understood. Methods To examine the role of the caspase-8 homolog cellular FLICE-inhibitory protein (c-FLIP) in liver injury, we generated mice with hepatocyte specific deletion of c-FLI…

LipopolysaccharidesProgrammed cell deathMAP Kinase Signaling SystemCASP8 and FADD-Like Apoptosis Regulating ProteinApoptosisGalactosamineBiologyCaspase 8MiceLiver diseaseConcanavalin AmedicineAnimalsfas ReceptorAnthracenesMice KnockoutLiver injuryHepatologyReceptors Death DomainFas receptormedicine.diseasemedicine.anatomical_structureApoptosisCaspasesHepatocyteDeath-inducing signaling complexHepatocytesCancer researchFemaleChemical and Drug Induced Liver InjuryJournal of Hepatology
researchProduct

Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP.

2012

Chronic liver disease promotes hepatocellular injury involving apoptosis and triggers compensatory regeneration that leads to the activation of quiescent stellate cells in the liver. The deposition of extracellular matrix from activated myofibroblasts promotes hepatic fibrosis and the progression to cirrhosis with deleterious effects on liver physiology. The role of apoptosis signaling pathways in the development of fibrosis remains undefined. The aim of the current study was to determine the involvement of the caspase-8 homologue cellular FLICE-inhibitory protein (cFLIP) during the initiation and progression of fibrosis. Liver injury and fibrosis from carbon tetrachloride (CCl4) and thioa…

Liver CirrhosisMalePathologymedicine.medical_specialtyTime FactorsGenotypePhysiologyCASP8 and FADD-Like Apoptosis Regulating ProteinApoptosisBiologyThioacetamideChronic liver diseaseMicePhysiology (medical)medicineAnimalsMitogen-Activated Protein Kinase 9PhosphorylationExtracellular Signal-Regulated MAP KinasesCarbon TetrachlorideCompensatory regenerationLiver injuryMice KnockoutHepatologyCaspase 3Gastroenterologymedicine.diseaseCaspase 9Enzyme ActivationDisease Models Animalmedicine.anatomical_structurePhenotypeLiverApoptosisHepatocyteHepatic stellate cellCancer researchDisease ProgressionHepatocytesHepatocellular injuryChemical and Drug Induced Liver InjuryHepatic fibrosisSignal TransductionAmerican journal of physiology. Gastrointestinal and liver physiology
researchProduct

Should cirrhosis change our attitude towards treating non-hepatic cancer?

2011

Cirrhosis is a major cause of morbidity and mortality and is the end stage of any chronic liver disease. Cancer, a leading cause of death worldwide, is a growing global health issue. There are limited data in the literature on the incidence, prevalence and management of non-hepatic cancers (NHC) in cirrhotic patients. The aim of this brief review was to underline the main concerns, pitfalls and warnings regarding practice for these patients. Survival of patients with compensated cirrhosis is significantly longer than that of decompensated cirrhosis and patients with NHC and in Child-Pugh class C should not be candidates for cytotoxic chemotherapy. It is important before starting cytotoxic c…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisAntineoplastic AgentsComorbidityChronic liver diseaseGastroenterologyLiver diseaseInternal medicineCause of DeathNeoplasmsmedicineHumansIntensive care medicineSurvival rateCause of deathHepatologybusiness.industryPatient SelectionCancerProfessional Practicemedicine.diseasechemotherapy – cirrhosis – hepatotoxicity – non-hepatic cancerClinical trialSurvival RateClinical Trials Phase III as TopicPortal hypertensionFemaleChemical and Drug Induced Liver InjurybusinessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity.

2012

Liver is the main detoxifying organ and therefore the target of high concentrations of genotoxic compounds, such as environmental carcinogens and anticancer drugs. Here, we investigated the usefulness of lovastatin, which is nowadays widely used for lipid lowering purpose, as a hepatoprotective drug following the administration of the anthracycline derivative doxorubicin in vivo. To this end, BALB/c mice were exposed to either a single high dose or three consecutive low doses of doxorubicin. Acute and subacute hepatotoxicities were analyzed with or without lovastatin co-treatment. Lovastatin protected the liver against doxorubicin-induced acute pro-inflammatory and pro-fibrotic stress respo…

Liver CirrhosisStatinAnthracyclinemedicine.drug_classBiologyPharmacologyToxicologymedicine.disease_causeMiceFibrosispolycyclic compoundsmedicineAnimalsDoxorubicinLovastatinRNA MessengerEpirubicinPharmacologyInflammationMice Inbred BALB CAntibiotics AntineoplasticDose-Response Relationship DrugConnective Tissue Growth Factormedicine.diseaseOxidative StressHepatoprotectionGene Expression RegulationDoxorubicinHMG-CoA reductasebiology.proteinlipids (amino acids peptides and proteins)LovastatinChemical and Drug Induced Liver InjuryHydroxymethylglutaryl-CoA Reductase InhibitorsOxidative stressmedicine.drugDNA DamageToxicology and applied pharmacology
researchProduct

Competency of different cell models to predict human hepatotoxic drugs.

2014

The liver is the most important target for drug-induced toxicity. This vulnerability results from functional liver features and its role in the metabolic elimination of most drugs. Drug-induced liver injury is a significant leading cause of acute, chronic liver disease and an important safety issue when developing new drugs.This review describes the advantages and limitations of hepatic cell-based models for early safety risk assessment during drug development. These models include hepatocytes cultured as monolayer, collagen-sandwich; emerging complex 3D configuration; liver-derived cell lines; stem cell-derived hepatocytes.In vitro toxicity assays performed in hepatocytes or hepatoma cell …

Liver cytologyCellPharmacologyBiologyToxicologyBioinformaticsChronic liver diseaseCell LineCell Line TumorToxicity TestsmedicineAnimalsHumansCells CulturedPharmacologyLiver injuryGeneral Medicinemedicine.diseasemedicine.anatomical_structureDrug developmentLiverCell cultureToxicityHepatic stellate cellHepatocytesChemical and Drug Induced Liver InjuryExpert opinion on drug metabolismtoxicology
researchProduct

Podoplanin discriminates distinct stromal cell populations and a novel progenitor subset in the liver

2015

Podoplanin/gp38+ stromal cells present in lymphoid organs play a central role in the formation and reorganization of the extracellular matrix and in the functional regulation of immune responses. Gp38+ cells are present during embryogenesis and in human livers of primary biliary cirrhosis. Since little is known about their function, we studied gp38+ cells during chronic liver inflammation in models of biliary and parenchymal liver fibrosis and steatohepatitis. Gp38+ cells were analyzed using flow cytometry and confocal microscopy, and the expression of their steady state and inflammation-associated genes was evaluated from healthy and inflamed livers. Gp38+ cells significantly expanded in …

Male0301 basic medicinePathologymedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BStromal cellPhysiologyLiver and Biliary Tract Physiology/PathophysiologyPopulationCell SeparationBiologyLiver Cirrhosis Experimental03 medical and health sciencesPrimary biliary cirrhosisAntigens CDNon-alcoholic Fatty Liver DiseasePhysiology (medical)medicineAnimalsAC133 AntigenProgenitor celleducationCells CulturedGlycoproteinsMice KnockoutLiver injuryeducation.field_of_studyMembrane GlycoproteinsMicroscopy ConfocalHepatologyLiver Cirrhosis BiliaryStem CellsLiver cellGastroenterologyFlow Cytometrymedicine.diseaseMolecular biologyMice Inbred C57BLPhenotype030104 developmental biologyGene Expression RegulationLiverChemical and Drug Induced Liver InjuryInflammation MediatorsStromal CellsStem cellSteatohepatitisPeptidesBiomarkersAmerican Journal of Physiology-Gastrointestinal and Liver Physiology
researchProduct

Potential hepatoprotective effects of new Cuban natural products in rat hepatocytes culture.

2008

The protective effects of five Cuban natural products (Mangifera indica L. (MSBE), Erythroxylum minutifolium, Erythroxylum confusum, Thalassia testudinum and Dictyota pinnatifida extracts and mangiferin) on the oxidative damage induced by model toxicants in rat hepatocyte cultures were studied. Cells were pre-incubated with the natural products (5-200 microg/mL) for 24 h. Then hepatotoxins (tert-butyl hydroperoxide, ethanol, carbon tetrachloride and lipopolysaccharide) were individually added and post-incubated for another 24 h. After treatments, cell viability was determined using the MTT assay. Mangiferin and MSBE exhibited the highest cytoprotective potential (EC50 between 50 and 125 mic…

MaleAntioxidantCell Survivalmedicine.medical_treatmentTetrazolium SaltsToxicologyChemopreventionAntioxidantsXenobioticsLipid peroxidationRats Sprague-Dawleychemistry.chemical_compoundMalondialdehydemedicineAnimalsMangiferinCells CulturedEC50Biological ProductsFormazansTraditional medicinebiologyDose-Response Relationship DrugCubaGeneral MedicineGlutathionebiology.organism_classificationGlutathioneErythroxylumRatsOxidative StressHepatoprotectionchemistryBiochemistryCarbon tetrachlorideHepatocytesMedicine TraditionalChemical and Drug Induced Liver InjuryToxicology in vitro : an international journal published in association with BIBRA
researchProduct

Acute and chronic hepatitis in childhood leukemia: a multicentric study from the Italian Pediatric Cooperative Group for Therapy of Acute Leukemia (A…

1985

The incidence of acute and chronic liver damage and its relation to hepatitis B virus (HBV) infection was evaluated in 164 consecutive children with acute leukemia seen in ten Italian hemato-pediatric units. Thirteen out of 164 children (7.9%) had acute hepatitis (AH) during treatment, while 8/90 (8.8%) showed an acute exacerbation of liver damage within 6 months after therapy withdrawal. Seven of the 13 children with AH while on therapy were HBsAg positive. In 12/13 cases, liver disease progressed to chronicity. Five of eight children who developed AH after completion of treatment were HBsAg positive. Eighty-nine patients (54.2%) developed biochemical evidence of chronic hepatitis during t…

MaleCancer Researchmedicine.medical_specialtyHBsAgChildhood leukemiaExacerbationAdolescentmedicine.disease_causeGastroenterologyacute hepatitisHepatitisLiver diseasechronic hepatitiLiver Function TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChildHepatitis B virusAcute leukemiaHepatitis B Surface AntigensLeukemiabusiness.industryLiver cellacute hepatitichildhood leukemiavirus diseasesInfantmedicine.diseaseacute hepatitis; chronic hepatitis; childhood leukemiaHepatitis BLeukemia LymphoidLeukemiaAcute and chronic hepatitis; childhood leukemia; multicentric study from AIEOPOncologyItalyChild PreschoolPediatrics Perinatology and Child HealthImmunologyAcute DiseaseFemalechronic hepatitisChemical and Drug Induced Liver InjurybusinessMedical and pediatric oncology
researchProduct

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the firs…

2016

BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma. We report the results of the first randomisation in this Article.METHODS: For the international randomised phase 2 International Extranodal Lymphoma Study Group-32 …

MaleComparative Effectiveness ResearchTransplantation ConditioningGastrointestinal DiseasesDenmarkMedizinKaplan-Meier EstimateDexamethasoneCentral Nervous System NeoplasmsDeath Sudden0302 clinical medicineIntraocular LymphomaGermanyAntineoplastic Combined Chemotherapy ProtocolsMedicineStandard treatmentOptic Nerve NeoplasmsPoisoningRemission InductionCytarabineHematopoietic Stem Cell TransplantationAnemiaHematologyInduction ChemotherapyAcute Kidney InjuryMiddle AgedCombined Modality TherapyMagnetic Resonance Imaging3. Good healthStrokeTreatment OutcomeTolerabilityItaly030220 oncology & carcinogenesischemoimmunotherapyRituximabFemaleNeurotoxicity SyndromesChemical and Drug Induced Liver InjuryRituximabSwitzerlandmedicine.drugMucositismedicine.medical_specialtyLymphoma B-CellNeutropeniaThioTEPAInfectionsTransplantation AutologousDisease-Free Survival03 medical and health sciencesprimary CNS lymphomaChemoimmunotherapyInternal medicineJournal Articleprimary CNS lymphoma chemoimmunotherapyHumansbusiness.industryThrombosismedicine.diseaseThrombocytopeniaUnited KingdomSurgeryTransplantationRegimenMethotrexateHeart InjuriesHyperglycemiaRadiotherapy Adjuvantbusiness030217 neurology & neurosurgeryFebrile neutropeniaThiotepaFollow-Up StudiesThe Lancet. Haematology
researchProduct

Effects of a preparation containing a standardized ginseng extract combined with trace elements and multivitamins against hepatotoxin-induced chronic…

1987

A preparation containing a standardized ginseng extract which has been shown to exert anti-hepatotoxic activity in vitro, combined with trace elements and multi-vitamins was compared to placebo in 24 elderly out-patients with toxin-induced (alcohol and drugs) chronic liver disease in order to evaluate its effect on liver function. Each patient was blindly treated either with the preparation containing ginseng extract or placebo for 12 weeks. The preparation containing ginseng extract significantly modified bromsulphthalein retention and blood zinc levels when compared to pre-treatment levels and to placebo. Serum bile acids, and γ-glutamyl transpeptidase before and after a fatty meal were …

MaleGinsenosidesmedicine.medical_treatment030204 cardiovascular system & hematologyPharmacologyChronic liver diseaseBiochemistrylaw.inventionGinsengRandom Allocation0302 clinical medicineRandomized controlled triallawClinical Trials as TopicLiver DiseasesHepatotoxinGeneral MedicineVitaminsgamma-GlutamyltransferaseMiddle AgedZincLiver030220 oncology & carcinogenesisDrug Therapy CombinationFemaleChemical and Drug Induced Liver Injurymedicine.medical_specialtyPanaxPlaceboBile Acids and Salts03 medical and health sciencesPharmacotherapyDouble-Blind MethodInternal medicinemedicineHumansAgedChemotherapyPlants Medicinalbusiness.industryBiochemistry (medical)Cell BiologySaponinsmedicine.diseaseDietary FatsTrace ElementsEndocrinologyChronic DiseaseLiver functionbusiness
researchProduct